Cost-per-Remission of Vedolizumab vs. Risankizumab for the Treatment of Moderate-to-Severely Active Crohn’s Disease in Italy, France, and Canada
Author(s)
Elizabeth Brook, MSc1, Chloë Hardern, MSc1, Jakob Langer, MSc2, Raffaella Viti, MSc3, Arnaud Nucit, PhD2, Cinira Lefevre, PhD4, Jun Yu Zhou, PharmD5.
1Putnam, London, United Kingdom, 2Takeda Pharmaceuticals International AG, Glattpark, Switzerland, 3Takeda Italia S.p.A., Rome, Italy, 4Takeda France SAS, Paris, France, 5Takeda Canada Inc., Toronto, ON, Canada.
1Putnam, London, United Kingdom, 2Takeda Pharmaceuticals International AG, Glattpark, Switzerland, 3Takeda Italia S.p.A., Rome, Italy, 4Takeda France SAS, Paris, France, 5Takeda Canada Inc., Toronto, ON, Canada.
OBJECTIVES: This economic analysis evaluated the cost-per-remission at 1-year for vedolizumab versus risankizumab in adult patients with moderate-to-severely active Crohn’s disease (CD) in Italy, France, and Canada. Cost-per-remission provides a transparent, short-term measure of value for decision-makers. Clinical remission was selected as the key endpoint, as it reflects sustained and meaningful disease control.
METHODS: Cost-per-remission was calculated as the total treatment cost over 1-year divided by the proportion of patients achieving clinical remission. Clinical remission was defined as a CD activity index score ≤150, with 1-year clinical remission rates sourced from a published matching-adjusted indirect comparison (MAIC)1. Treatment costs included drug acquisition and administration costs of vedolizumab and risankizumab, based on the number of administrations over 1-year according to the respective licensed dosing schedules. Drug list prices and administration costs were country-specific. To assess result sensitivity, scenario analyses using the 95% confidence intervals from the MAIC were conducted to estimate best- and worst-case outcomes. A price-discount sensitivity analysis was conducted to compare the cost-per-remission at varying drug discount levels for each treatment.
RESULTS: In all countries assessed, vedolizumab had a lower cost-per-remission at 1 year than risankizumab (Italy: -62%; France: -66%; Canada: -51%) in CD. Findings remained consistent across scenario analyses; even with substantial discounts to risankizumab’s list price, vedolizumab maintained a lower cost-per-remission.
CONCLUSIONS: Across Italy, France, and Canada, vedolizumab was associated with a lower cost-per-remission than risankizumab in CD. These findings suggest that vedolizumab may offer a more efficient use of treatment resources to achieve clinical remission in adult patients with moderate-to-severely active CD across multiple healthcare settings.
References
1. V Jairath, et al. P1061 A matching-adjusted indirect comparison (MAIC) of vedolizumab vs risankizumab in patients with moderately-to-severely active Crohn’s disease, Journal of Crohn's and Colitis, Volume 19, Issue Supplement 1, January 2025, Pages i1956-i1958, https://doi.org/10.1093/ecco-jcc/jjae190.1235
METHODS: Cost-per-remission was calculated as the total treatment cost over 1-year divided by the proportion of patients achieving clinical remission. Clinical remission was defined as a CD activity index score ≤150, with 1-year clinical remission rates sourced from a published matching-adjusted indirect comparison (MAIC)1. Treatment costs included drug acquisition and administration costs of vedolizumab and risankizumab, based on the number of administrations over 1-year according to the respective licensed dosing schedules. Drug list prices and administration costs were country-specific. To assess result sensitivity, scenario analyses using the 95% confidence intervals from the MAIC were conducted to estimate best- and worst-case outcomes. A price-discount sensitivity analysis was conducted to compare the cost-per-remission at varying drug discount levels for each treatment.
RESULTS: In all countries assessed, vedolizumab had a lower cost-per-remission at 1 year than risankizumab (Italy: -62%; France: -66%; Canada: -51%) in CD. Findings remained consistent across scenario analyses; even with substantial discounts to risankizumab’s list price, vedolizumab maintained a lower cost-per-remission.
CONCLUSIONS: Across Italy, France, and Canada, vedolizumab was associated with a lower cost-per-remission than risankizumab in CD. These findings suggest that vedolizumab may offer a more efficient use of treatment resources to achieve clinical remission in adult patients with moderate-to-severely active CD across multiple healthcare settings.
References
1. V Jairath, et al. P1061 A matching-adjusted indirect comparison (MAIC) of vedolizumab vs risankizumab in patients with moderately-to-severely active Crohn’s disease, Journal of Crohn's and Colitis, Volume 19, Issue Supplement 1, January 2025, Pages i1956-i1958, https://doi.org/10.1093/ecco-jcc/jjae190.1235
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE284
Topic
Economic Evaluation
Disease
Gastrointestinal Disorders, No Additional Disease & Conditions/Specialized Treatment Areas